OKLAHOMA CITY, Okla. – A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function. University of Oklahoma researcher Matthew Potthoff,...

The filing is based on the results from an investigator-initiated Japanese phase II clinical study evaluating Tecentriq in combination with carboplatin and paclitaxel, the standard chemotherapy regimen for unresectable thymic carcinoma as first-line treatment Designated as an orphan drug, making it eligible for priority review If approved, Tecentriq would become...

COPENHAGEN, Denmark — Ascendis Pharma A/S (Nasdaq: ASND) today announced new data showing improvements in growth and bone morphometry from Week 52 of its pivotal ApproaCH Trial of TransCon CNP (navepegritide) in children with achondroplasia. TransCon CNP is an investigational prodrug of C-type natriuretic peptide (CNP) administered once weekly providing...